Serotonin–norepinephrine reuptake inhibitor

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

Retrieved on: 
Martedì, Maggio 7, 2024
Hebrew University of Jerusalem, Selective serotonin reuptake inhibitor, Weight gain, Hope, Post-traumatic stress disorder, Nausea, PTSD, Al-Quds, Insomnia, Serotonin–norepinephrine reuptake inhibitor, Therapy, Intellectual property, Anxiety, Pharmaceutical industry

This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University.

Key Points: 
  • This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University.
  • These novel compounds are targeted at treating post-traumatic stress disorder (PTSD) and other mental health conditions.
  • The global market for PTSD treatment, valued at $16.8 billion in 2023, is expected to reach $27.37 billion by 2033, according to Future Market Insights.
  • Under the terms of the agreement, Clearmind receives exclusive rights to develop, manufacture, and commercialize novel compounds for treating PTSD and other mental health disorders.

BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program

Retrieved on: 
Martedì, Maggio 16, 2023
Volunteering, Index, Depression, Orthostatic hypotension, Dexmedetomidine, Half-life, Somnolence, Schizophrenia, Hypotension, Anxiety, Safety, Tolerability, Bipolar II disorder, Pharmacokinetics, DSM-IV codes, Disorder, Selective serotonin reuptake inhibitor, Dizziness, MDD, Patient, BID, Artificial intelligence, MTD, MAD, Intermittent explosive disorder, Serotonin–norepinephrine reuptake inhibitor, POC, Therapy, Headache, III, Agitation, Pharmaceutical industry, Vaccine, Neuroscience, HAVEN

NEW HAVEN, Conn., May 16, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced positive top-line data from its Phase 1b multiple ascending dose (MAD) trial of BXCL501 (dexmedetomidine) sublingual film. BXCL501 is the Company’s proprietary, orally dissolving film under investigation for the treatment of agitation associated with neuropsychiatric disorders and as a potential adjunctive treatment in Major Depressive Disorder (MDD).

Key Points: 
  • The trial was designed to evaluate the safety and tolerability of repeat dosing of BXCL501 in healthy volunteers as a single agent and in combination with antidepressant duloxetine.
  • “This positive outcome supports the potential market expansion opportunity for our lead asset, BXCL501, into chronic neuropsychiatric disorders,” said Vimal Mehta, CEO of BioXcel Therapeutics.
  • We believe these new data present a transformative opportunity beyond acute treatment for the BXCL501 program, including treatment for MDD.
  • The study’s primary objectives were to assess the safety, tolerability, and pharmacokinetics of BXCL501 in healthy volunteers in multiple ascending doses.

Global Diabetic Neuropathic Pain Market Report to 2031: Players Include AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and GlaxoSmithKline - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Maggio 15, 2023
Diabetes, Pharmaceutical, Health, Calcium channel, DNP, Gabapentinoid, Diagnosis, Analgesic, TCA, AGR, Serotonin, Serotonin–norepinephrine reuptake inhibitor, Therapy, Epidemiology, Patient, Investment, Dietary supplement, Pharmaceutical industry, Retail

Annualized diabetic neuropathic pain therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.

Key Points: 
  • Annualized diabetic neuropathic pain therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the diabetic neuropathic pain therapeutics market.
  • Analysis of the current and future market competition in the global diabetic neuropathic pain therapeutics market.
  • Develop business strategies by understanding the trends shaping and driving the global diabetic neuropathic pain therapeutics market.

Vella Bioscience Inc. Granted First Patent For Use of Cannabinoids in Treating Antidepressant-Induced Female Sexual Dysfunction

Retrieved on: 
Mercoledì, Marzo 29, 2023
Patent, FRCS, Cannabinoid, Woman, Attitude, Science, Selective serotonin reuptake inhibitor, United States Patent and Trademark Office, Pleasure, Serotonin–norepinephrine reuptake inhibitor, Health, FDA, Female, Pharmaceutical industry, MD, CBD

NEW YORK, March 29, 2023 /PRNewswire/ -- Vella Bioscience Inc. whose Women's Pleasure Serum has been dubbed the "Women's Viagra®," has announced today that the Patent and Trademark Office (USPTO) has granted the brand's first patent. The patent is for the use of cannabinoids in treating Antidepressant-Induced Female Sexual Dysfunction.

Key Points: 
  • whose Women's Pleasure Serum has been dubbed the "Women's Viagra®," has announced today that the Patent and Trademark Office (USPTO) has granted the brand's first patent.
  • The patent is for the use of cannabinoids in treating Antidepressant-Induced Female Sexual Dysfunction.
  • As a company, we bring a certain 'the future-is-now' attitude to women's sexual empowerment and pleasure that is wholly unique."
  • Vella's patent establishes it as a pioneer in the clinical beauty space of female sexual health and wellness and proves its commitment to science and innovation.

Antidepressant Tapering Platform Outro Launches in Canada Ahead of World Tapering Day

Retrieved on: 
Martedì, Novembre 1, 2022
Technology, Mental Health, Health Technology, Software, Health, Pharmaceutical, General Health, Other Science, Science, Awareness, Dizziness, Sertraline, Grammatical mood, Psychotherapy, Citalopram, Method, Serotonin–norepinephrine reuptake inhibitor, Risk, COVID-19, Paroxetine, Headache, Technology, Anxiety, Selective serotonin reuptake inhibitor, Patient, Fluoxetine, Depression, Pharmaceutical industry, Online shopping, Facebook, Outro, Instagram

Outro , the first-of-its-kind platform harnessing technology and specialized care to help people reduce or stop the use of antidepressants, announces its launch in Canada ahead of World Tapering Day on November 5.

Key Points: 
  • Outro , the first-of-its-kind platform harnessing technology and specialized care to help people reduce or stop the use of antidepressants, announces its launch in Canada ahead of World Tapering Day on November 5.
  • Outros user-friendly platform provides science-based, personalized tapering plans to slowly reduce medication dosage.
  • We are incredibly excited to bring this platform to many in need across Canada, said Brandon Goode, co-founder and chief executive officer of Outro.
  • Outro is poised to help many in Canada and eventually more around the world.

Madrigal Mental Care Develops Treatment for Post-Traumatic Stress Disorder Based on Psychedelic Drugs

Retrieved on: 
Lunedì, Maggio 9, 2022
Transfer, People, Ben-Gurion University of the Negev, LSD, Psilocybin, Selective serotonin reuptake inhibitor, Tic disorder, Lysergic acid diethylamide, Department, Brain, Senior, Biochemistry, Student, Post-traumatic stress disorder, Lists of diseases, Company, Ketamine, Incubator, Nanoparticle, Depression, PayPal, Time, Cognition, Norepinephrine, Nanotechnology, Entrepreneurship, BGU, BGN, Diagnosis, Serotonin, Business development, Deutsche Telekom, Anxiety, Pharmacology, Patent, Serotonin–norepinephrine reuptake inhibitor, Wallace H. Coulter Department of Biomedical Engineering, MDMA, Trauma, Dell EMC, Mescaline, Psychotherapy, Government Hospital For Mental Care, PTSD, Technology, Research, Lockheed, Growth, Association of British HealthTech Industries, InterContinental, Online gambling, Pharmaceutical industry, BIOMED

BEER-SHEVA, Israel, May 9, 2022 /PRNewswire/ -- Madrigal Mental Care, a biopharmaceutical company developing a breakthrough delivery system for psychedelic drugs, introduces its novel nanotechnology for the treatment and prevention of post-traumatic stress disorder (PTSD) at Biomed Israel 2022, the premier international Life Science and HealthTech conference in Israel, on May 10-12, 2022, at the David InterContinental Hotel in Tel Aviv, Israel.

Key Points: 
  • "An increasing number of studies point to the advantages of using psychedelic drugs for the treatment of psychiatric disorders such as PTSD, depression, anxiety, obsessive compulsive disorder, and even addiction, with low doses," said Prof. Sintov.
  • The nanoparticles are biodegradable and provide a significant advantage over common practices in terms of stability and accuracy," stated David Gabay, Co-Founder, and Chairman of Madrigal Mental Care.
  • Based on Databridge, the psychedelic market is expected to reach 40$ billion by 2027 in the medical arena alone.
  • Madrigal Mental Care aims to redefine the future of mental health care by using cutting-edge, breakthrough nanotechnology to deliver psychedelic drugs.

BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada

Retrieved on: 
Giovedì, Settembre 9, 2021

RALEIGH, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.

Key Points: 
  • ELYXYB is the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.
  • ELYXYBs unit-dose oral solution makes it convenient for patients to take it immediately upon emergence of acute migraine attacks.
  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.
  • ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

Selective Serotonin Reuptake Inhibitors (SSRIs) Market- AbbVie Inc., Apotex Inc., Aurobindo Pharma Ltd., among others to contribute to the market growth|Industry Analysis, Market Trends, Opportunities and Forecast 2025

Retrieved on: 
Venerdì, Aprile 2, 2021
Selective serotonin reuptake inhibitors, Pharmacology, Branches of biology, Drugs, Serotonin reuptake inhibitor, Serotonin, Reuptake inhibitor, Serotonin–norepinephrine reuptake inhibitor, Allosteric serotonin reuptake inhibitor

The selective serotonin reuptake inhibitors (SSRIs) market is poised to grow by $ 809.73 mnduring 2021-2025, progressing at a CAGR ofabout 4% during the forecast period.

Key Points: 
  • The selective serotonin reuptake inhibitors (SSRIs) market is poised to grow by $ 809.73 mnduring 2021-2025, progressing at a CAGR ofabout 4% during the forecast period.
  • The report on the selective serotonin reuptake inhibitors (SSRIs) market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • This study identifies the growing geriatric population as one of the prime reasons driving the selective serotonin reuptake inhibitors (SSRIs) market growth during the next few years.
  • The selective serotonin reuptake inhibitors (SSRIs) market covers the following areas:

Do Commonly Prescribed Antidepressants Increase the Risk of Bleeding Stroke?

Retrieved on: 
Mercoledì, Marzo 3, 2021
Psychoactive drugs, Drugs, Chemical compounds, Selective serotonin reuptake inhibitors, Antidepressant, Serotonin, Serotonin–norepinephrine reuptake inhibitor, Serotonin–norepinephrine–dopamine reuptake inhibitor

MINNEAPOLIS, March 3, 2021 /PRNewswire/ --There is good news for people who take antidepressants called selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants in the United States.

Key Points: 
  • MINNEAPOLIS, March 3, 2021 /PRNewswire/ --There is good news for people who take antidepressants called selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants in the United States.
  • The most common causes are high blood pressure and head trauma, but some studies have also suggested that SSRIs may increase a person's risk of this type of bleeding stroke.
  • "However, by interfering with serotonin, which also plays a role in blood clotting, SSRIs may increase the risk of bleeding.
  • Therefore, to determine if these antidepressants increase the risk of bleeding strokes, we looked at a large population of people with stroke."

OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for the Treatment of Major Depressive and Generalized Anxiety Disorder

Retrieved on: 
Mercoledì, Luglio 8, 2020
Psychoactive drugs, RTT, Serotonin-norepinephrine reuptake inhibitors, Antidepressants, Chemical compounds, Psychiatry, Amines, Duloxetine, Thiophenes, Serotonin–norepinephrine reuptake inhibitor, Generalized anxiety disorder, Norepinephrine reuptake inhibitor

Duloxetine hydrochloride is a serotonin and norepinephrine reuptake inhibitor (SNRI) and the delayed-release capsules, for oral use, were first approved in the U.S. in 2004.

Key Points: 
  • Duloxetine hydrochloride is a serotonin and norepinephrine reuptake inhibitor (SNRI) and the delayed-release capsules, for oral use, were first approved in the U.S. in 2004.
  • In major depressive and generalized anxiety disorders, duloxetine hydrochloride is indicated for treatment in adults.
  • If approved, this would represent the first-ever powder for oral liquid formulation available for duloxetine hydrochloride.
  • Healthcare providers may also find that in this form, the dosage may be easier to titrate and adjust.